BACKGROUND: The aim of this study was to determine whether the combined use of the C-reactive protein (CRP) level and neutrophil-lymphocyte ratio (NLR) before treatment predicts disease-specific survival in adult patients with soft tissue sarcoma (STS). METHODS: We retrospectively reviewed 142 patients who presented with STS between 1995 and 2010. RESULTS: The NLR varied from 0.54 to 7.59. An elevated CRP level was observed in 36 patients before treatment. The patients with both an elevated CRP level and high NLR had a poorer disease-specific survival (46% at 5 years) than the patients with both a normal CRP level and low NLR (87% at 5 years) (P = 0.0005). The patients with both an elevated CRP level and high NLR also had a poorer disease-specific survival than the patients with either an elevated CRP level or high NLR (75.6% at five years) (P = 0.03). There were no significantly prognostic differences between the patients with a normal CRP level and low NLR and those with either an elevated CRP level or high NLR (P = 0.18). A multivariate analysis also showed the preoperative NLR and CRP level to be independent predictors of survival. CONCLUSIONS: We recommend the routine measurement of these markers to identify patients with a greater risk of death.
BACKGROUND: The aim of this study was to determine whether the combined use of the C-reactive protein (CRP) level and neutrophil-lymphocyte ratio (NLR) before treatment predicts disease-specific survival in adult patients with soft tissue sarcoma (STS). METHODS: We retrospectively reviewed 142 patients who presented with STS between 1995 and 2010. RESULTS: The NLR varied from 0.54 to 7.59. An elevated CRP level was observed in 36 patients before treatment. The patients with both an elevated CRP level and high NLR had a poorer disease-specific survival (46% at 5 years) than the patients with both a normal CRP level and low NLR (87% at 5 years) (P = 0.0005). The patients with both an elevated CRP level and high NLR also had a poorer disease-specific survival than the patients with either an elevated CRP level or high NLR (75.6% at five years) (P = 0.03). There were no significantly prognostic differences between the patients with a normal CRP level and low NLR and those with either an elevated CRP level or high NLR (P = 0.18). A multivariate analysis also showed the preoperative NLR and CRP level to be independent predictors of survival. CONCLUSIONS: We recommend the routine measurement of these markers to identify patients with a greater risk of death.
Authors: M Giuliani; L R Sampson; O Wong; J Gay; L W Le; B C J Cho; A Brade; A Sun; A Bezjak; A J Hope Journal: Curr Oncol Date: 2016-08-12 Impact factor: 3.677
Authors: Mio Yanagisawa; Alicia A Gingrich; Sean Judge; Chin-Shang Li; Nana Wang; Steven W Thorpe; Amanda R Kirane; Richard J Bold; Arta M Monjazeb; Robert J Canter Journal: Anticancer Res Date: 2018-03 Impact factor: 2.480
Authors: M H Kang; S-I Go; H-N Song; A Lee; S-H Kim; J-H Kang; B-K Jeong; K M Kang; H Ling; G-W Lee Journal: Br J Cancer Date: 2014-06-12 Impact factor: 7.640